The environmental impact of treating macular disease.
作者信息
Irwin Chris, Williams Michael
机构信息
Northern Ireland Medical and Dental Training Agency, Belfast, Northern Ireland, UK.
Centre for Medical Education, Queen's University of Belfast, Belfast, Northern Ireland, UK.
出版信息
Eye (Lond). 2023 Oct;37(15):3063-3064. doi: 10.1038/s41433-023-02486-z. Epub 2023 Mar 10.
Abstract
摘要
相似文献
1
The environmental impact of treating macular disease.治疗黄斑疾病对环境的影响。
Eye (Lond). 2023 Oct;37(15):3063-3064. doi: 10.1038/s41433-023-02486-z. Epub 2023 Mar 10.
2
Cell-based approaches towards treating age-related macular degeneration.基于细胞的方法治疗年龄相关性黄斑变性。
Cell Tissue Bank. 2020 Sep;21(3):339-347. doi: 10.1007/s10561-020-09826-3. Epub 2020 Mar 10.
3
The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences.美国年龄相关性黄斑变性的双生子研究：遗传和环境影响的相对作用。
Arch Ophthalmol. 2005 Mar;123(3):321-7. doi: 10.1001/archopht.123.3.321.
4
How genetic studies have advanced our understanding of age-related macular degeneration and their impact on patient care: a review.遗传研究如何增进我们对年龄相关性黄斑变性的认识及其对患者护理的影响：综述。
Clin Exp Ophthalmol. 2014 Jan-Feb;42(1):53-64. doi: 10.1111/ceo.12235. Epub 2013 Oct 28.
5
CKD increases the risk of age-related macular degeneration.慢性肾脏病会增加年龄相关性黄斑变性的风险。
J Am Soc Nephrol. 2008 Apr;19(4):806-11. doi: 10.1681/ASN.2007080844. Epub 2008 Jan 23.
6
Oxidative stress as a therapeutic target for the prevention and treatment of early age-related macular degeneration.氧化应激作为预防和治疗早发性年龄相关性黄斑变性的治疗靶点。
Surv Ophthalmol. 2021 May-Jun;66(3):423-440. doi: 10.1016/j.survophthal.2020.09.002. Epub 2020 Sep 19.
7
Pharmaceutical composition for treating macular degeneration (WO2012079419).用于治疗黄斑变性的药物组合物（WO2012079419）。
Expert Opin Ther Pat. 2013 Feb;23(2):269-72. doi: 10.1517/13543776.2013.751972. Epub 2012 Dec 10.
8
Macular degeneration: types, causes, and possible interventions.黄斑变性：类型、病因及可能的干预措施。
Geriatr Nurs. 2007 Nov-Dec;28(6):387-92. doi: 10.1016/j.gerinurse.2007.03.003.
9
Senile macular degeneration: a case-control study.老年性黄斑变性：一项病例对照研究。
Am J Epidemiol. 1983 Aug;118(2):213-27. doi: 10.1093/oxfordjournals.aje.a113629.
10
1,25-Dihydroxyvitamin D decreases HTRA1 promoter activity in the rhesus monkey--a plausible explanation for the influence of vitamin D on age-related macular degeneration?1,25-二羟维生素 D 降低食蟹猴 HTRA1 启动子活性——维生素 D 影响年龄相关性黄斑变性的一种合理假说？
Exp Eye Res. 2013 Nov;116:234-9. doi: 10.1016/j.exer.2013.09.012. Epub 2013 Sep 27.
本文引用的文献
1
Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre.描述接受每季度阿柏西普治疗的新生血管性年龄相关性黄斑变性患者的治疗结局：来自大型三级护理中心的真实世界临床结局。
Eye (Lond). 2023 Mar;37(4):779-784. doi: 10.1038/s41433-022-02220-1. Epub 2022 Sep 9.
2
Intravitreal injections: past trends and future projections within a UK tertiary hospital.玻璃体腔内注射：英国一家三级医院内的过去趋势和未来预测。
Eye (Lond). 2022 Jul;36(7):1373-1378. doi: 10.1038/s41433-021-01646-3. Epub 2021 Jun 25.
3
Systematic review: non-adherence and non-persistence in intravitreal treatment.系统评价：玻璃体内治疗的不依从和不持续。
Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2077-2090. doi: 10.1007/s00417-020-04798-2. Epub 2020 Jun 22.
4
Psychological impact of anti-VEGF treatments for wet macular degeneration-a review.抗血管内皮生长因子治疗湿性黄斑变性的心理影响——综述
Graefes Arch Clin Exp Ophthalmol. 2016 Oct;254(10):1873-1880. doi: 10.1007/s00417-016-3384-0. Epub 2016 Jun 4.
5
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.随机、假手术对照试验研究地塞米松眼内植入剂治疗视网膜静脉阻塞所致黄斑水肿患者。
Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24.
Zotero 插件